Full-Time

Business Unit Director

Medtech Surgery

Posted on 7/13/2026

Deadline 7/20/26
Johnson & Johnson

Johnson & Johnson

10,001+ employees

Global healthcare company offering pharma, devices.

No salary listed

Bracknell, UK

Hybrid

Hybrid work arrangement; on-site presence in Wokingham, Berkshire as required.

Bachelor's

Category
Business & Strategy (1)
Required Skills
Sales
Financial analysis
Marketing

Get referred to Johnson & Johnson

See people who can refer or advise you

Requirements
  • Degree in science/medicine and/or business
  • Minimum 5 years’ experience of leading a commercial organisation with P&L responsibility
  • Over 5 years of leadership experience in a BU with > 30 people / $50M
  • Experience in the MedTech UK market and category knowledge in Wound Closure and Healing is a plus
  • Experience leading a commercial organization with P&L responsibility is essential
  • Strong business & financial acumen with strategic mindset
  • Proven customer centricity and knowledge of economic environment and market dynamics
  • Strong patient and external environment orientation
  • Track record of building networks and partnerships with external leaders
  • Credo-based leadership and Health Care Compliance culture
  • Strong organizational leadership and ability to lead through change
  • Talent development mindset and developing diverse leaders
  • Strong communication and influencing skills
  • Demonstrated enterprise mindset and ability to collaborate in a global, matrixed environment
  • Travel availability 50%-75%
Responsibilities
  • As member of the UKI Surgery Leadership Team, lead the sales and marketing team for the Wound Closure (WC) business
  • Develop, implement and deliver the business sales and marketing strategy in cross-functional collaboration with local leadership team, Marketing, ProfEd, HEMA, Medical and Government Affairs as well as global & regional stakeholders
  • Represent UK and Ireland on regional and Global Platform Leadership Teams
  • Ensuring the development and delivery of consolidated plans for short-term and long-term profitable growth
  • Drive profitable growth by flawlessly implementing plans, while continuing to deliver product launch excellence, the right resource allocations on capabilities, skills and talent as well as deliver against BP targets to optimize growth and win in the marketplace
  • Direct & monitor financial and budget activities to achieve financial goals. This includes partnering with Finance; owning and managing the P&L conducting financial planning, analysis and modelling and anticipating trends and making key decisions that impact short- and long-term financial performance
  • Set strategy in alignment with regional and global direction and work to understand and consider opportunities from other markets when planning and implementing business strategies
  • Drive national execution for these platforms and specialties
  • Shape the external environment by developing deep customer and competitor insights & relationships with clinical and non-clinical stakeholders (government policymakers, health-care executives, purchasing groups); leverage market insights and new strategic/commercial capabilities to create new commercial models and innovative solutions that drive growth and every stakeholder value
  • Lead a high performing sales and marketing team and create an agile and customer-focused organisation
  • Develop a robust pipeline of diverse leaders with skills to succeed in a complex and dynamic marketplace and champion initiatives to promote an inclusive workplace environment and highly engaged workforce
  • Install growth mindset within the team, ensuring effective communication and employee engagement, talent selection whilst minimizing organisation disruption and ensuring continuous business acceleration
  • Create a Credo aligned culture, ensuring Health Care Compliance and integrity principles are championed and actively practiced at every level of the organisation
Desired Qualifications
  • Brand Marketing
  • Brand Positioning Strategy
  • Business Alignment
  • Business Storytelling
  • Business Valuations
  • Consulting
  • Critical Thinking
  • Cross-Functional Collaboration
  • Customer Intelligence
  • Data Analysis
  • Data-Driven Decision Making
  • Developing Others
  • Execution Focus
  • Financial Analysis
  • Go-to-Market Strategies
  • Inclusive Leadership
  • Industry Analysis
  • Leadership
  • Market Research
  • Negotiation
  • Problem Solving
  • Product Development Lifecycle
  • Product Portfolio Management
  • Product Strategies
  • {+ 3 more}

Johnson & Johnson operates in three main areas—pharmaceuticals, medical devices, and consumer health products—serving consumers, healthcare professionals, and institutions worldwide. It develops prescription medicines, sells surgical and vision care devices, and offers over-the-counter and personal care products, funded by direct sales, partnerships, and distribution agreements, with heavy investment in research and development. The company differentiates itself by combining three complementary businesses under one umbrella and maintaining a global footprint with an emphasis on science, innovation, and inclusive culture. Its goal is to help people live healthier lives by delivering reliable, high-quality healthcare products and solutions that improve patient outcomes.

Company Size

10,001+

Company Stage

IPO

Headquarters

New Brunswick, New Jersey

Founded

1886

Get referred to Johnson & Johnson

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 sales hit $25.3 billion, and guidance rose to $101.1 billion.
  • TREMFYA, INLEXZO, and ICOTYDE are accelerating, offsetting STELARA's 55% quarterly collapse.
  • FDA-cleared OTTAVA begins US commercialization, expanding J&J's robotic surgery platform this year.

What critics are saying

  • The July 2026 talc settlement leaves future claims unresolved and UK litigation active.
  • STELARA biosimilars and Imbruvica competition keep eroding legacy pharma cash flows in 2026.
  • Abiomed weakened after the UK Impella study, and PROTECT IV data arrives in 2027.

What makes Johnson & Johnson unique

  • J&J spans pharmaceuticals, MedTech, and consumer brands across entrenched hospital workflows.
  • Its scale funds constant launches, from TREMFYA to OTTAVA, across multiple therapies.
  • Deep surgeon and hospital switching costs protect MedTech franchises like da Vinci-adjacent competitors.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Paid Holidays

Remote Work Options

Performance Bonus

Growth & Insights and Company News

Headcount

6 month growth

-4%

1 year growth

-4%

2 year growth

-2%
Yahoo Finance
Aug 4th, 2026
JNJ returns $85B to shareholders but stock still lags S&P 500 by 13%

Johnson & Johnson returned $85 billion to shareholders over the past five years through $60 billion in dividends and $25 billion in share buybacks, equivalent to 13.8% of its current market capitalisation. The healthcare giant generated $97.93 billion in revenue over the last twelve months with a 27% operating margin. Despite this substantial cash return, JNJ shareholders saw a total return of 70% over five years, underperforming the S&P 500's 83% return. The company's Innovative Medicine division showed strong performance, with double-digit growth excluding STELARA and successful launches like ICOTYDE. However, the MedTech segment struggled, particularly in cardiovascular, where the Abiomed heart pump business saw sales decline 2%. The performance gap between divisions raises questions about whether returning cash signals disciplined capital allocation or a shortage of high-return growth opportunities.

Yahoo Finance
Jul 31st, 2026
J&J beats estimates with $25.3B revenue, raises guidance to $101.1B for the year

Johnson & Johnson reported strong Q2 2026 results with sales rising nearly 7% to $25.31 billion, beating estimates of $25.05 billion. Adjusted earnings per share reached $2.90, surpassing the expected $2.85. The company raised its full-year guidance and remains on track to exceed $100 billion in annual revenue for the first time in its 140-year history. Its pharmaceutical division generated $16.38 billion in quarterly sales. Despite a 55% drop in Stelara revenue to $740 million due to patent loss, newer drugs compensated for the decline. Tremfya sales surged 72.5% to $2 billion, well above the $1.74 billion estimate. Meanwhile, Danaher delivered encouraging Q2 results driven by its Life Sciences business, with bioprocessing orders growing mid-teens despite timing-related revenue fluctuations.

Yahoo Finance
Jul 28th, 2026
J&J to pay $5.5B to settle 76,000 talc baby powder cancer lawsuits

Johnson & Johnson has agreed to pay $5.5 billion to settle approximately 76,000 lawsuits alleging its talc-based baby powder caused ovarian cancer. The settlement requires acceptance by at least 95% of claimants to take effect. The company expects to make an initial payment of no more than $3 billion in 2027, with additional payments due from 2028. Legal representatives suggest the total payout could reach $7 billion or more. The deal is designed to deliver payment to all claimants within 18 months and covers only current claims, leaving future lawsuits outside its scope. J&J maintains the claims lack merit but said the settlement allows it to move forward. The agreement follows three years of halted proceedings whilst J&J pursued unsuccessful bankruptcy strategies through a subsidiary. The company withdrew its talc-based baby powder from US shelves in 2020 and worldwide in 2023.

Yahoo Finance
Jul 27th, 2026
J&J's MedTech sales rise 4.5% to $8.93B in Q2 amid Abiomed weakness and electrophysiology pressure

Johnson & Johnson's MedTech segment delivered mixed second-quarter 2026 results. Sales rose 4.5% to $8.93 billion but missed the consensus estimate of $8.96 billion. The shortfall stemmed from weaker cardiovascular performance, particularly in Abiomed, where sales declined 2% due to slow procedural volumes for the Impella heart pump. Physician uncertainty following a UK study questioning Impella's benefit in certain high-risk procedures contributed to reduced usage. Despite cardiovascular weakness, J&J's Surgery, Vision, and Orthopedics businesses accelerated above expectations, growing 3.9%, 6.0%, and 4.9% respectively. Shockwave revenues rose 14.6% to $335 million. J&J characterised the Abiomed issue as temporary and noted stable overall procedure volumes across its MedTech business, with no meaningful impact from expired Affordable Care Act subsidies.

Yahoo Finance
Jul 27th, 2026
J&J exec sells $5.8M in shares as stock climbs 27% despite biosimilar and competition headwinds

Johnson & Johnson executive Vanessa Broadhurst sold 23,054 shares worth approximately $5.8 million on 20 July, representing about half her stake. The stock has risen 27% this year. J&J has restructured through recent spin-offs of its consumer health and orthopaedics units to focus on higher-growth areas. Management targets 6% operational sales growth for 2026, aiming for double-digit growth by decade's end. Recent quarterly revenue increased 6.6% year-over-year, with oncology up 17.3%. Darzalex grew nearly 18%, whilst Tremfya surged 72.5%. Management raised full-year earnings guidance. However, older blockbuster Stelara declined due to biosimilar competition, and Imbruvica dropped 18.5% on competitive pressure. The stock trades at roughly 21-22 times forward earnings, about 10% above sector median, with a 2.2% dividend yield.

INACTIVE